Compare MYFW & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYFW | HELP |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.6M | 249.0M |
| IPO Year | 2018 | N/A |
| Metric | MYFW | HELP |
|---|---|---|
| Price | $26.75 | $5.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $25.50 | ★ $95.00 |
| AVG Volume (30 Days) | 23.9K | ★ 726.8K |
| Earning Date | 04-23-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.02 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $96,914,000.00 | N/A |
| Revenue This Year | $20.48 | N/A |
| Revenue Next Year | $9.70 | N/A |
| P/E Ratio | $19.62 | ★ N/A |
| Revenue Growth | ★ 7.60 | N/A |
| 52 Week Low | $17.66 | $4.29 |
| 52 Week High | $28.00 | $8.55 |
| Indicator | MYFW | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 70.89 | 48.81 |
| Support Level | $22.20 | $4.40 |
| Resistance Level | $27.30 | $8.55 |
| Average True Range (ATR) | 0.55 | 0.31 |
| MACD | 0.27 | 0.15 |
| Stochastic Oscillator | 89.29 | 82.76 |
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.